Indeed, the treatment of leukemic cells with the specific inhibitor CP1B, derived from calpastatin, affects the expression and secretion of MMP-2/MMP-9, reducing matrix degradation and thus tumor invasion (71). Here, MMP2 is linked to neoplasm.